¼ÓÈëVIP ÉÏ´«¿¼²©×ÊÁÏ ÄúµÄÁ÷Á¿ Ôö¼ÓÁ÷Á¿ ¿¼²©±¨°à ÿÈÕÇ©µ½
   
Ö÷Ìâ : Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)
¼¶±ð: ×ܰæÖ÷
ÏÔʾÓû§ÐÅÏ¢ 
Â¥Ö÷  ·¢±íÓÚ: 2007-01-25   

Ò»¾Å¾Å¾ÅÄ격ʿÉúÈëѧ¿¼ÊÔÊÔÌâ(רҵ»ù´¡: ÃâÒßѧ)

Ò»¾Å¾Å°ËÄ격ʿÑо¿ÉúÈëѧ¿¼ÊÔÊÔÌâ hu?Q,[+o  
-^ ) 0c  
£¨ÃâÒßѧרҵºÍרҵ»ù´¡£© gN2$;hb?  
uvN Lm]*  
Ò».Ãû´Ê½âÊÍ£¨Ã¿Ìâ3·Ö£¬¹²45·Ö£© xvP=i/SO  
i!H)@4jX  
1.Co-stimulators (or co-stimulating molecules) 4o+SSS  
"4Joou"U  
2.NK-kB ]} D^?g^  
2nNBX2 o&_  
3.Immunoglobulin superfamily ^!Y]l  
4?+K:e #F  
4.antigen-presenting cell (APC) Rm@#GP`  
]!7 %)  
5.death domain 9CBKU4JQ  
3.i$lp`t  
6.CCR and CXCR QO1pwrX<  
|PGF g0li  
7.Lectin (or mitogen) u|;?FQ$M  
xwuGJ   
8.Clusters of differentiation, CD) o,-p [1b  
&a;{ed1B  
9.B7 family #$5"&SM  
PK C}!>2  
10.Cytotoxic T lymphocyte, CTL) Hw0S/ytY  
4*AkUkP:T  
11.IL-15 and IL-15 receptor (IL-15R) a&^HvXO(>(  
'E\/H17  
12.MHC restriction CP]nk0  
/)%$xi  
13.Affinity-chromatography v3p0  
}3825  
14.Cyctosprin A, CsA `EXo=Dqc  
3_DwqZ 'O  
15.Antibody-dependent cell-mediated cytotoxicity, ADCC) Ci-CY/]s  
u=6LPwiI  
¶þ.ÎÊ´ðÌ⣨ÿÌâ10·Ö£¬¹²30·Ö£© GhJ<L3  
`4SwdW n  
1.ºÎΪTh1ºÍ Th2ÑÇȺ£¿ÈçºÎ¼ì²â£¿ÔÚÁÙ´²ÉÏÓкÎÒâÒ壿 Ad}Nc"O  
La2f]+sV  
2.ÊÔÊöÃâÒßÇòµ°°×£¨Ig£©µÄ½á¹¹Ó빦ÄܵĹØÏµ¡£ \ u*R6z  
#+"1">l  
3.ÊԱȽÏTϸ°ûÊÜÌ壨TCR/CD3£©ÓëBϸ°ûÊÜÌ壨BCR£©µÄ×é³É¡¢½á¹¹¼°Æäʶ±ð ¿¹Ô­µÄÌØµã¡£ C8Oh]JF4d  
Y 9}ga4  
Èý.Ñ¡ÔñÎÊ´ðÌ⣨¸÷רҵ¿¼ÉúÖ»´ðÒ»µÀ±¾×¨ÒµÊÔÌ⣬25·Ö£© .A Dik}o  
<eh<4_<qF  
ÃâÒßѧרҵ£º ;RW0Dn)Q  
T5_/*`F  
1.ÊÔÊöB7/CD28, CTLA-4£¬CD40/CD40L£¬LFA-1/ICAM-1£¬CD2/LFA-3µÄ½á¹¹¡¢·Ö²¼ÒÔ¼°Ï໥×÷Óúó½éµ¼µÄÖ÷ÒªÉúÎïѧ¹¦ÄÜ¡£ a5k![sw\  
1CR)1H  
Ïû»¯ÄÚ¿Æ£º O>@ ChQF  
vNDf1B5z  
2.Ö×Áö¿¹Ô­·ÖΪÄļ¸Àࣿ»úÌ忹Ö×ÁöÃâÒßÖ÷ÒªÓÐÄÄЩÒòËØ£¨»úÖÆ£©£¿¼òÊöÌá¸ß¿¹Ö×ÁöÃâÒßÑо¿µÄÂԲߡ£ |e_'% d&  
;%Zu[G`C  
ѪҺ²¡Ñ§×¨Òµ£º 'PvOOhm,  
~]Weyb[ N  
3.ºÎΪ°×Ѫ²¡µÄÃâÒßѧ·ÖÐÍ£¿ºÎÎªÒÆÖ²ÎËÞÖ÷·´Ó¦£*****VHR£©£¿GVHR·¢ÉúµÄÖ÷ÒªÔ­Òò£¨Ìõ¼þ£©ÊÇʲô£¿
ÆÀ¼ÛÒ»ÏÂÄãä¯ÀÀ´ËÌû×ӵĸÐÊÜ

¾«²Ê

¸Ð¶¯

¸ãЦ

¿ªÐÄ

·ßÅ­

ÎÞÁÄ

¹àË®

  
ÃèÊö
¿ìËٻظ´

ÑéÖ¤ÎÊÌâ:
5+2=? ÕýÈ·´ð°¸:7
°´"Ctrl+Enter"Ö±½ÓÌá½»